Palbocib 125 mg Palbociclib (1 bottle — 21 caps)

Buy Palbocib 125 mg Palbociclib Capsules Online

Palbocib 125 mg Palbociclib Capsules (1 bottle / 21 caps)

Մի հայացքով

Ընդհանուր անվանում՝ Palbociclib

Բրենդի անվանումը՝ Palbocib 125 mg

Հզորությունը և փաթեթի չափը՝ 125 mg capsules, 1 bottle / 21 capsules

Դեղաչափի ձևը և ընդունման եղանակը. Hard gelatin capsules for oral use

Թերապևտիկ դաս. CDK4/6 inhibitor targeted therapy

Հիմնական ցուցումներ՝ Hormone receptor-positive, HER2-negative advanced or metastatic breast cancer in adults, in combination with endocrine therapy as per local label

Typical Patient Profile: Adults with HR-positive, HER2-negative breast cancer where CDK4/6 inhibition is appropriate based on specialist assessment

Գործողության եղանակը՝ Selectively inhibits cyclin-dependent kinases 4 and 6 to arrest cell-cycle progression in tumour cells

Հիմնական առավելությունները՝ Improved progression-free outcomes when combined with endocrine therapy in eligible patients, with an oral, at-home dosing schedule

Նախազգուշական միջոցներ: Requires regular blood count monitoring, assessment for infections, liver tests and effective contraception; use only under oncology supervision

Պահեստավորում՝ Store in the original bottle below the temperature stated on the pack, tightly closed and protected from moisture, out of the reach of children

Արտադրանքի նկարագրություն

Palbocib 125 mg պարունակում է palbociclib, բանավոր cyclin-dependent kinase (CDK) 4/6 inhibitor used in combination with endocrine therapy for hormone receptor-positive, HER2-negative advanced or metastatic breast cancer. Rather than acting as classic cytotoxic chemotherapy, palbociclib is a targeted therapy designed to disrupt key cell-cycle regulators that drive uncontrolled proliferation in HR-positive breast cancer cells.

Each bottle of Palbocib 125 mg palbociclib capsules մատակարարված է Ջեներիկ դեղերի շուկա contains 21 capsules, reflecting a standard 21-day “on treatment” period in a typical 28-day cycle when the medicine is used according to its approved schedule. The 125 mg strength is frequently chosen as the starting dose for many adults, with dose adjustments made by the treating oncologist if neutropenia or other side effects arise. Palbocib 125 mg is almost always prescribed alongside endocrine therapy such as an aromatase inhibitor or fulvestrant, forming a combination regimen that targets both hormonal signalling and cell-cycle control.

Ջեներիկ դեղերի շուկա աղբյուրներ Palbocib 125 mg palbociclib capsules only from licensed manufacturers and authorised distributors. Each bottle and outer carton displays the brand name, strength, generic name, batch number and expiry date so that oncology pharmacies can verify the medicine before dispensing. Parcels are shipped in neutral outer packaging without visible references to breast cancer or targeted therapy, supporting patient privacy while maintaining full traceability through invoices and batch documentation. Our role is limited to access and logistics; all treatment decisions remain with your oncology team.

Հիմնական կիրառություններ

Palbocib 125 mg palbociclib capsules are used as part of systemic therapy for hormone receptor-positive, HER2-negative advanced or metastatic breast cancer in adults, according to local prescribing information and guidelines. Typical uses include:

• Use with an aromatase inhibitor as initial endocrine-based therapy for postmenopausal women and other eligible adults with HR-positive, HER2-negative advanced or metastatic breast cancer.
• Use with fulvestrant in patients whose disease has progressed after prior endocrine therapy, where a CDK4/6 inhibitor remains appropriate.
• Use in carefully selected patient groups where dual targeting of hormone signalling and CDK4/6-mediated cell-cycle pathways is expected to improve disease control compared with endocrine therapy alone.

Exact positioning of Palbocib 125 mg within the treatment pathway depends on prior therapies, menopausal status, comorbidities, tumour burden and local practice. The choice of partner endocrine therapy and sequencing relative to other systemic agents is always determined by a specialist.

How Palbociclib Works in Chemotherapy

Palbociclib, ակտիվ բաղադրիչը Palbocib 125 mg, is a selective inhibitor of cyclin-dependent kinases 4 and 6. These kinases form complexes with D-type cyclins and play a central role in regulating transition from the G1 to S phase of the cell cycle, a checkpoint that determines whether a cell proceeds to DNA synthesis and division. In hormone receptor-positive breast cancer, CDK4/6 activity is often upregulated, contributing to uncontrolled proliferation.

By inhibiting CDK4 and CDK6, palbociclib reduces phosphorylation of the retinoblastoma (Rb) protein, a gatekeeper of G1-to-S progression. Reduced Rb phosphorylation keeps the cell-cycle checkpoint engaged, leading to G1 arrest and limiting proliferation of sensitive tumour cells. When combined with endocrine therapy that reduces or blocks estrogen-driven signalling, palbociclib helps slow tumour growth, delay progression and extend the duration of response in many patients with HR-positive, HER2-negative metastatic disease.

Դեղաչափ և կիրառում

Palbocib 125 mg palbociclib capsules must only be prescribed and monitored by oncologists experienced in treating advanced breast cancer with CDK4/6 inhibitors. The commonly used schedule is 125 mg taken once daily for 21 consecutive days, followed by 7 days off treatment, forming a 28-day cycle. Palbociclib is given alongside a companion endocrine therapy, which may be taken continuously or on its own schedule depending on the product used.

Capsules should be swallowed whole with water and should not be chewed, opened or crushed. Patients are usually advised to take Palbocib 125 mg at approximately the same time each day and to follow the instructions in the patient leaflet regarding food. If a dose is missed or vomited, patients should follow their oncologist’s or pharmacist’s advice rather than doubling the next dose. Before each cycle and at defined points during therapy, complete blood counts and other tests are performed. Dose reductions or interruptions may be required if neutropenia, thrombocytopenia or other toxicities reach predefined thresholds.

Նախազգուշական միջոցներ

Մինչև սկսելը Palbocib 125 mg, the oncology team will review the patient’s prior treatments, blood counts, liver function, concomitant medicines and infection risk. Palbociclib can cause clinically significant neutropenia, increasing susceptibility to infections, so patients should be educated about promptly reporting fever or signs of illness. Strong inhibitors or inducers of CYP3A may alter palbociclib exposure and often need to be avoided or managed carefully.

Effective contraception is strongly recommended for people of childbearing potential during palbociclib therapy և կանգ առնելուց հետո որոշ ժամանակ, ինչպես palbociclib may harm a developing fetus. Breastfeeding is generally not recommended while taking Palbocib 125 mg. Patients should inform their care team about any planned procedures, new medicines or herbal supplements, and should never adjust their palbociclib dose without medical advice.

Palbociclib Side Effects

Հաճախակի կողմնակի ազդեցություններ

Ընդհանուր palbociclib side effects հիվանդների մոտ, որոնք ընդունում են Palbocib 125 mg include neutropenia and leukopenia, often detected on routine blood tests, as well as fatigue, nausea, decreased appetite, diarrhoea, constipation, mild stomatitis or mouth sores, hair thinning, low-grade infections, headache and mild elevations in liver enzymes. Many of these effects are manageable with supportive care, cycle-by-cycle monitoring and dose modifications. Patients are routinely counselled on infection precautions and when to seek urgent care.

Լուրջ կողմնակի ազդեցություններ

Լուրջ palbociclib adverse effects require urgent medical attention and may include febrile neutropenia or severe infections, severe or persistent neutropenia, significant thrombocytopenia with bleeding, pronounced liver enzyme elevations, interstitial lung disease or pneumonitis, and very rare severe hypersensitivity reactions. Warning signs include high fever, chills, shortness of breath, persistent cough, chest pain, unexplained bruising or bleeding, dark urine, yellowing of the skin or eyes or severe fatigue and weakness. If any of these occur while using Palbocib 125 mg palbociclib capsules, emergency medical review is essential and treatment may need to be interrupted or adjusted.

Պահեստավորում

Palbocib 125 mg capsules should be stored in the original bottle with the cap tightly closed, at or below the temperature stated on the carton, and protected from moisture. The bottle should be kept out of the sight and reach of children and should not be stored in the bathroom or other humid environments. Capsules must not be used after the expiry date on the label, and any unused or expired palbociclib should be returned to a pharmacy or disposed of via an approved medicines take-back programme, not in household waste or wastewater.

Ինչու՞ գնել Ջեներիկ Մեդս Մարթից

Ջեներիկ դեղերի շուկա is dedicated to improving access to targeted oncology medicines such as Palbocib 125 mg palbociclib capsules for patients with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer. We work only with licensed manufacturers and authorised exporters that follow recognised quality standards and maintain documented batch traceability. Each bottle is supplied in sealed original packaging so that treating oncologists and pharmacy teams can confirm the product name, strength, batch number and expiry before advising patients.

All orders are processed in ԱՄՆ դոլար through secure checkout, and shipments are packed in discreet, neutral outer packaging that does not mention breast cancer or targeted therapy. Where available, trackable shipping options help patients and clinics coordinate refills so that palbociclib cycles can continue without unnecessary interruptions. Our role is limited to logistics and access; decisions about when to start, adjust or stop Palbocib 125 mg therapy remain entirely with your oncology specialists.

Պատվիրեք հիմա

Պատվիրելուց առաջ Palbocib 125 mg palbociclib capsules -ից Ջեներիկ դեղերի շուկա, you should have a clear treatment plan from your oncologist specifying that a CDK4/6 inhibitor combined with endocrine therapy is appropriate for your breast cancer and detailing the intended dose, cycle structure and monitoring schedule. Your team will explain the goals of therapy, expected time course of response, possible side effects and when to contact the clinic urgently.

Once this plan is in place, you can select Palbocib 125 mg (1 bottle / 21 caps), choose the number of bottles needed for your prescribed cycles and complete secure checkout in ԱՄՆ դոլար. Medicines will be dispatched in discreet packaging with documentation including product and batch details for your records and for your oncology pharmacy. You should never start, stop or change palbociclib dosing without specialist guidance, and any concerning symptom during treatment should be reported promptly so your team can adjust your care safely.

Հաճախակի տրվող հարցեր about Palbocib (Palbociclib)

Հարց 1: What is Palbocib 125 mg used for?
Palbocib 125 mg պարունակում է palbociclib, մի CDK4/6 inhibitor used in combination with endocrine therapy for hormone receptor-positive, HER2-negative advanced or metastatic breast cancer in adults, according to local prescribing information and oncology guidelines.

Հարց 2: Is Palbocib 125 mg a form of chemotherapy?
Palbocib 125 mg համարվում է թիրախային թերապիա rather than traditional cytotoxic chemotherapy. It interferes with CDK4/6-mediated cell-cycle progression in cancer cells, but it is still a potent anticancer medicine and must be used under close specialist supervision with regular monitoring.

Հարց 3: How long will I need to stay on palbociclib treatment?
Many patients remain on palbociclib-based therapy for as long as it continues to control the disease and side effects remain manageable. The optimal duration varies between individuals and depends on response, tolerability and the availability of alternative options. Only your oncology team can decide how long you should continue Palbocib 125 mg.

Հարց 4: Can I miss or delay a dose of Palbocib 125 mg?
If you miss a dose or vomit after taking a capsule, you should follow the instructions from your oncologist or patient leaflet. In general, you should not double your next dose to make up for one that was missed. Any questions about missed doses or delays should be discussed with your care team, who may adjust your schedule if needed.

Հարց 5: Do I need special blood tests while on Palbocib 125 mg?
Yes. Regular blood tests are an essential part of palbociclib therapy, especially to monitor white blood cell and neutrophil counts, platelets and liver function. These tests help your team decide whether it is safe to start a new cycle, whether dose adjustments are needed and how to manage any side effects that arise.